Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti‐TNF‐α antibody infliximab

Yazdani‐Biuki, Babak; Stelzl, H; Brezinschek, Hans‐Peter; Hermann, Josef; Mueller, Thomas; Krippl, Peter; Graninger, Winfried; Wascher, Thomas C.

doi:10.1111/j.1365-2362.2004.01390.x

Cited by 132 publications

(86 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings extend those of previous small studies showing improvement in insulin sensitivity with either steroid or sulfasalazine therapy in RA (for review, see ref. 32) and are consistent with a recent case report series of patients with RA and PsA, 3 of whom exhibited substantial reductions in homeostasis model assessment scores after treatment with infliximab (12). There are plentiful mechanisms potentially explaining links between cytokines such as TNF and impaired insulin action (34).…”

supporting

confidence: 84%

“…In other words, inflammation may be a critical factor explaining the association of homocysteine and Lp(a) with vascular risk in conditions of high-grade inflammation such as RA and perhaps, by extrapolation, in conditions of low-grade inflammation. Finally, the treatment-induced increase in SHBG levels was sizable (ϳ40%), and although SHBG levels are admittedly an indirect measure of insulin sensitivity, these data concur with enhanced insulin sensitivity upon suppression of inflammation (12). TNF blockade is now used widely in the treatment of chronic inflammatory autoimmune disorders.…”

Section: Discussionmentioning

confidence: 77%

“…Specifically, we used a robust placebocontrolled study design to determine whether modulating TNF (and thus dampening systemic inflammation) would improve lipid levels, and whether Lp(a), ICAM-1, and homocysteine concentrations would decrease, as predicted from cross-sectional analyses of the association of these parameters with inflammation. Finally, we examined whether SHBG concentrations would increase, in keeping with an apparent inverse association of insulin sensitivity and inflammation (1,12). The clinical outcome of the patients in this trial will be reported separately.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

Sattar

Crompton

Cherry

et al. 2007

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

Objective. To conduct a robust, double-blind, placebo-controlled study examining the effects of tumor necrosis factor (TNF) modulation on concentrations of traditional and novel cardiovascular disease risk factors in patients with an inflammatory condition.Methods. In this double-blind study, 127 patients with psoriatic arthritis (PsA) and active psoriasis were randomized to 1 of 3 treatment arms (placebo, onercept 50 mg, or onercept 100 mg for 12 weeks). Traditional and novel biochemical risk factors were evaluated at baseline and at the end of the treatment period.Results. At baseline, an elevated C-reactive protein ( Conclusion. This study is the first to demonstrate that targeting the TNF pathway can significantly decrease Lp(a) and homocysteine levels and elevate Apo A-I and SHBG concentrations. These data support an important precursor role for high-grade inflammation in modulating these putative risk parameters. However, TNF blockade-induced increases in triglyceride and Apo B levels were unexpected and suggest that it is not possible, on the basis of biochemical changes in isolation, to suggest that cardioprotection would necessarily follow; rather, direct measures of atherosclerotic progression with TNF blockade (e.g., using carotid ultrasound) would be better.

show abstract

supporting

confidence: 84%

Section: Discussionmentioning

confidence: 77%

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

Sattar

Crompton

Cherry

et al. 2007

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

show abstract

“…This outcome seems to confirm the beneficial effects of anti-TNF- Moabs already documented in many RA studies (Huvers et al, 2007;Yazdani-Biuki et al, 2004). In particular, infliximab has proved capable of enhancing insulin sensitivity after the infusion to up to one year (Huvers et al, 2007).…”

Section: Frequent Side Effectssupporting

confidence: 72%

The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients

Amedei¹,

D’Elios²

2012

Psoriasis

View full text Add to dashboard Cite

“…27 TNF-α causes impaired insulin-derived peripheral uptake of glucose by increasing the serine phosphorylation of insulin receptor substrate 1 (IRS-1) and consequently inhibits the translocation of glucose transporter type 4 (GLUT4) to the plasma membrane, which results in peripheral IR. 28,29 Some studies have suggested that treatment with anti-TNF-α antibody can improve insulin sensitivity in IR patients 30,31 . IL-6 is another inflammatory adipokine that is involved the pathogenesis of IR.…”

Section: Discussionmentioning

confidence: 99%

Glycemic control and adipokines after periodontal therapy in patients with Type 2 diabetes and chronic periodontitis

Wang

Liu²,

Zhang³

et al. 2017

Braz. oral res.

View full text Add to dashboard Cite

Abstract:The mechanism by which chronic periodontitis (CP) affects type 2 diabetes (T2DM) remains unclear. Therefore, the aim of this study is to evaluate the effects of periodontal therapy (PT) on the glycemic control and adipokines of patients with T2DM and CP with the purpose of elucidating the possible mechanisms by which CP influences T2DM. Forty-four patients with T2DM and CP were randomly divided into two groups according to whether they underwent PT. Periodontal status, blood glucose, and the levels of serum tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), adiponectin (APN), and fibroblast growth factor-21 (FGF-21) were measured at baseline and after 3 months. The results revealed that the probing depth (PD) and attachment loss (AL) were significantly improved, the serum levels of TNF-α and IL-6 were significantly decreased, and APN and FGF-21 exhibited substantial increases in the intervention group after 3 months (p < 0.05), whereas no significant changes were observed in the control group. The glycated hemoglobin (HbA1c) levels in both groups decreased significantly after 3 months compared with baseline (p < 0.05), but the intervention group exhibited a significantly greater change (p < 0.05). In conclusion, PT may relieve periodontal inflammation, which causes a reduction of insulin-antagonizing adipokines and an increase in insulin-sensitizing adipokines, thereby eliciting an improvement in glycemic control.

show abstract

Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti‐TNF‐α antibody infliximab

Cited by 132 publications

References 10 publications

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients

Glycemic control and adipokines after periodontal therapy in patients with Type 2 diabetes and chronic periodontitis

Contact Info

Product

Resources

About